Radiopharmaceutical developer Navidea Biopharmaceuticals posted upticks in revenue and a lower net loss in its second quarter of 2015.
For the quarter (end-June 30), the company reported revenues of $2.9 million, compared with $1.1 million for the same period in 2014. Navidea's net loss for the quarter was $9.7 million, compared with $10.2 million for the same period in 2014.
Navidea saw $1.9 million in Lymphoseek sales for the quarter, compared with $1 million in the same period last year.
The company continues to expect Lymphoseek revenue of $10 million to $12 million in 2015.
